CY1108087T1 - ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟΛΙΟΥ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TAFIa - Google Patents
ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟΛΙΟΥ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TAFIaInfo
- Publication number
- CY1108087T1 CY1108087T1 CY20081100491T CY081100491T CY1108087T1 CY 1108087 T1 CY1108087 T1 CY 1108087T1 CY 20081100491 T CY20081100491 T CY 20081100491T CY 081100491 T CY081100491 T CY 081100491T CY 1108087 T1 CY1108087 T1 CY 1108087T1
- Authority
- CY
- Cyprus
- Prior art keywords
- tafia
- imidazoli
- suspensions
- products
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Η εφεύρεση αφορά σε ενώσεις του τύπου (Ia), οι οποίες είναι αναστολείς της ινωδόλυσης που μπορεί να ενεργοποιηθεί από ενεργοποιημένη θρομβίνη. Οι ενώσεις του τύπου Ia είναι κατάλληλες για την παρασκευή φαρμάκων για την προφύλαξη και θεραπεία παθήσεων, που εξελίσσονται με θρομβώσεις, εμβολές, υπερπηκτικότητα ή ινωσικές μεταβολές.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004020186A DE102004020186A1 (de) | 2004-04-22 | 2004-04-22 | Heterocyclylessigsäuren als Inhibitoren von TAFla |
| EP05731221A EP1740569B1 (de) | 2004-04-22 | 2005-04-07 | Imidazol-derivate als tafia-inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1108087T1 true CY1108087T1 (el) | 2014-02-12 |
Family
ID=34964308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081100491T CY1108087T1 (el) | 2004-04-22 | 2008-05-12 | ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟΛΙΟΥ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TAFIa |
Country Status (35)
| Country | Link |
|---|---|
| EP (2) | EP1740569B1 (el) |
| JP (1) | JP4939401B2 (el) |
| KR (1) | KR101162047B1 (el) |
| CN (1) | CN100572376C (el) |
| AR (1) | AR053302A1 (el) |
| AT (2) | ATE523505T1 (el) |
| AU (1) | AU2005238144B2 (el) |
| BR (1) | BRPI0510159A (el) |
| CA (1) | CA2563401C (el) |
| CR (1) | CR8650A (el) |
| CY (1) | CY1108087T1 (el) |
| DE (2) | DE102004020186A1 (el) |
| DK (1) | DK1740569T3 (el) |
| EC (1) | ECSP066941A (el) |
| ES (1) | ES2299026T3 (el) |
| HK (1) | HK1101823A1 (el) |
| HR (1) | HRP20080099T3 (el) |
| IL (1) | IL178672A (el) |
| MA (1) | MA28543B1 (el) |
| MY (1) | MY140903A (el) |
| NI (1) | NI200600217A (el) |
| NO (1) | NO20065320L (el) |
| NZ (1) | NZ550757A (el) |
| PE (1) | PE20060172A1 (el) |
| PL (1) | PL1740569T3 (el) |
| PT (1) | PT1740569E (el) |
| RS (1) | RS50553B (el) |
| RU (1) | RU2375356C2 (el) |
| SI (1) | SI1740569T1 (el) |
| TN (1) | TNSN06341A1 (el) |
| TW (1) | TWI359016B (el) |
| UA (1) | UA87306C2 (el) |
| UY (1) | UY28868A1 (el) |
| WO (1) | WO2005105781A1 (el) |
| ZA (1) | ZA200607668B (el) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2104497E (pt) | 2006-12-06 | 2015-06-09 | Sanofi Sa | Derivados de ureia e sulfamida enquanto inibidores de tafia |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| WO2008100459A1 (en) * | 2007-02-13 | 2008-08-21 | Schering Corporation | Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists |
| AU2008279447A1 (en) * | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| WO2009103432A2 (en) * | 2008-02-21 | 2009-08-27 | Sanofi-Aventis | Covalently binding imaging probes |
| SI2300462T1 (sl) * | 2008-06-06 | 2014-09-30 | Sanofi | Makrociklični sečninski in sulfamidni derivati kot inhibitorji za TAFIa |
| CA2741783A1 (en) | 2008-10-29 | 2010-05-06 | Taisho Pharmaceutical Co., Ltd. | Compounds having tafia inhibitory activity |
| SG176558A1 (en) * | 2009-05-15 | 2012-01-30 | Sanofi Sa | Process for the preparation of a compound useful as an inhibitor of tafia |
| FR2947266B1 (fr) * | 2009-06-26 | 2011-06-17 | Servier Lab | Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN102666553B (zh) | 2009-10-01 | 2015-05-06 | 赛马拜制药公司 | 取代的四唑-1-基-苯氧基甲基-噻唑-2-基-哌啶基-嘧啶盐 |
| CN105801489B (zh) * | 2010-03-18 | 2019-12-10 | 第一三共株式会社 | 环烷基取代的咪唑衍生物 |
| JP5778133B2 (ja) | 2010-03-18 | 2015-09-16 | 第一三共株式会社 | シクロプロパンカルボン酸誘導体 |
| AU2011328263A1 (en) | 2010-11-11 | 2013-05-30 | Sanofi | Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives |
| EP2782576B1 (en) | 2011-11-25 | 2016-05-18 | Sanofi | Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid |
| EP2782575B1 (en) | 2011-11-25 | 2016-04-20 | Sanofi | Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid |
| US9156815B2 (en) | 2011-11-25 | 2015-10-13 | Sanofi | Salt of (R)-3-(6-amino-pyridin-3-yl)-2-(1-Cyclohexyl-1H-imidazol-4-yl) ethyl propionate |
| EP2805705B1 (en) | 2013-05-23 | 2016-11-09 | IP Gesellschaft für Management mbH | Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid |
| AU2014280329A1 (en) * | 2013-06-10 | 2016-01-07 | Sanofi | Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals |
| KR20180123038A (ko) | 2016-03-29 | 2018-11-14 | 다이이찌 산쿄 가부시키가이샤 | 염증성 장질환 치료제 |
| US10292983B2 (en) | 2016-08-03 | 2019-05-21 | Cymabay Therapeutics, Inc. | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003013526A1 (en) | 2001-08-08 | 2003-02-20 | Merck & Co. Inc. | Anticoagulant compounds |
| MXPA04005940A (es) | 2002-01-22 | 2004-09-13 | Pfizer | Acidos 3-(imidazolil)-2-aminopropanoicos. |
-
2004
- 2004-04-22 DE DE102004020186A patent/DE102004020186A1/de not_active Withdrawn
-
2005
- 2005-04-06 PE PE2005000382A patent/PE20060172A1/es not_active Application Discontinuation
- 2005-04-07 WO PCT/EP2005/003630 patent/WO2005105781A1/de active Application Filing
- 2005-04-07 EP EP05731221A patent/EP1740569B1/de active Active
- 2005-04-07 BR BRPI0510159-0A patent/BRPI0510159A/pt not_active Application Discontinuation
- 2005-04-07 SI SI200530185T patent/SI1740569T1/sl unknown
- 2005-04-07 RU RU2006141246/04A patent/RU2375356C2/ru not_active IP Right Cessation
- 2005-04-07 PT PT05731221T patent/PT1740569E/pt unknown
- 2005-04-07 AU AU2005238144A patent/AU2005238144B2/en not_active Ceased
- 2005-04-07 EP EP07017340A patent/EP1864979B1/de active Active
- 2005-04-07 AT AT07017340T patent/ATE523505T1/de active
- 2005-04-07 DK DK05731221T patent/DK1740569T3/da active
- 2005-04-07 NZ NZ550757A patent/NZ550757A/en not_active IP Right Cessation
- 2005-04-07 PL PL05731221T patent/PL1740569T3/pl unknown
- 2005-04-07 CN CNB2005800115593A patent/CN100572376C/zh not_active Expired - Fee Related
- 2005-04-07 CA CA2563401A patent/CA2563401C/en not_active Expired - Fee Related
- 2005-04-07 JP JP2007508756A patent/JP4939401B2/ja not_active Expired - Fee Related
- 2005-04-07 AT AT05731221T patent/ATE386737T1/de active
- 2005-04-07 DE DE502005002927T patent/DE502005002927D1/de active Active
- 2005-04-07 KR KR1020067021881A patent/KR101162047B1/ko not_active IP Right Cessation
- 2005-04-07 RS RSP-2008/0107A patent/RS50553B/sr unknown
- 2005-04-07 ES ES05731221T patent/ES2299026T3/es active Active
- 2005-04-20 TW TW094112493A patent/TWI359016B/zh not_active IP Right Cessation
- 2005-04-20 MY MYPI20051748A patent/MY140903A/en unknown
- 2005-04-20 AR ARP050101556A patent/AR053302A1/es not_active Application Discontinuation
- 2005-04-22 UY UY28868A patent/UY28868A1/es unknown
- 2005-07-04 UA UAA200612254A patent/UA87306C2/ru unknown
-
2006
- 2006-09-13 ZA ZA200607668A patent/ZA200607668B/en unknown
- 2006-09-20 NI NI200600217A patent/NI200600217A/es unknown
- 2006-09-22 CR CR8650A patent/CR8650A/es unknown
- 2006-10-17 IL IL178672A patent/IL178672A/en not_active IP Right Cessation
- 2006-10-19 MA MA29399A patent/MA28543B1/fr unknown
- 2006-10-20 TN TNP2006000341A patent/TNSN06341A1/en unknown
- 2006-10-20 EC EC2006006941A patent/ECSP066941A/es unknown
- 2006-11-20 NO NO20065320A patent/NO20065320L/no not_active Application Discontinuation
-
2007
- 2007-09-03 HK HK07109537.4A patent/HK1101823A1/xx not_active IP Right Cessation
-
2008
- 2008-03-06 HR HR20080099T patent/HRP20080099T3/xx unknown
- 2008-05-12 CY CY20081100491T patent/CY1108087T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108087T1 (el) | ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟΛΙΟΥ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TAFIa | |
| CY1117379T1 (el) | Παραγωγα ιμιδαζολιου ως αναστολεις toy tafi-a | |
| CY1116384T1 (el) | Παραγωγα σουλφαμιδιου ως αναστολεις tafia | |
| CY1120246T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
| CY1119077T1 (el) | Παραγωγα πυραζολυλαμινοπυριδινης χρησιμα ως αναστολεις κινασων | |
| EA201100311A1 (ru) | Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы | |
| CY1118143T1 (el) | Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1 | |
| CY1110108T1 (el) | Παραγωγα ισοκινολινης ως αναστολεις της rho-κινασης | |
| CY1113560T1 (el) | Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων | |
| DK1853602T3 (da) | Kemiske forbindelser | |
| DK1853588T3 (da) | Kemiske forbindelser | |
| CY1113192T1 (el) | Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora | |
| NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
| ATE510827T1 (de) | Inhibitoren von proteinkinasen | |
| CY1115604T1 (el) | Μακροκυκλικα παραγωγα ουριας και σουλφαμιδης ως αναστολεις των ταfια | |
| EA202091530A1 (ru) | Диазаиндольные соединения | |
| EA201170052A1 (ru) | Производные тиофена или тиазола и их применение как ингибиторов pi3k | |
| EA200601697A1 (ru) | Производные карболина, полезные в ингибировании ангиогенеза | |
| NO20082266L (no) | Nye 1-azabicykloalkylderivater for behandling av psykotiske og neurodegenerative forstyrrelser | |
| EA200801608A1 (ru) | Производные бензимидазолонкарбоновой кислоты | |
| CR9378A (es) | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias | |
| NO20085135L (no) | Selektive inhibitorer av ROCK-proteinkinase og anvendelse derav | |
| EA201000895A1 (ru) | Композиции и способы для лечения лизосомных болезней | |
| EA200700400A1 (ru) | Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии | |
| CY1113257T1 (el) | Παραγωγα βενζυλοπιπεραζινης τα οποια ειναι χρησιμα στη θεραπεια γαστρεντερικων διαταραχων |